来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 成曦累计任职时间9年187天，现任基金资产总规模2501.21亿元，任职期间最佳基金回报131.04%， 任 职期间最差基金回报-67.89%。 从君实生物十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 易方达上证科创板50ETF（58 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 前海联合国民健康混合A（003581）成立日期2016年12月29日，最新规模1564.76万。今年以来收益 6.95%，同类排名6475/8148；近一年收益0.76%，同类排名7710/8053；成立以 ...

Core Viewpoint - The company, Junshi Biosciences, aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation in drug development [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020. Its main business involves the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with 90.67% of revenue coming from drug sales [7]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8]. Product Development - The company has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Collaborations and Research - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in the preclinical development stage [3][8]. Market Performance - On November 7, the company's stock fell by 1.92%, with a trading volume of 292 million yuan and a market capitalization of 38.799 billion yuan [1]. - The stock has seen a net outflow of 458.376 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 41.33 yuan, with the current price approaching a resistance level of 38.99 yuan, suggesting potential volatility in the near term [6].

Core Viewpoint - The biopharmaceutical sector on the STAR Market has shown mixed performance, with the STAR Biopharmaceutical Index declining by 0.60% as of November 6, 2025, while individual stocks exhibited varied movements, indicating a potential for structural recovery in the sector [1][4]. Group 1: Market Performance - The STAR Biopharmaceutical Index decreased by 0.60% as of November 6, 2025, with stocks like Huaheng Biological leading gains at 2.86%, while Yifang Biological experienced the largest decline [1]. - The Jiashi STAR Biopharmaceutical ETF recorded a turnover of 6.67% and a transaction volume of 21.39 million yuan, reaching a new high of 322 million yuan in scale, ranking first among comparable funds [3]. - The Jiashi STAR Biopharmaceutical ETF has seen a net inflow of 56.85 million yuan over the past four days, with a peak single-day net inflow of 16.85 million yuan [3]. Group 2: Fund Performance - As of November 5, 2025, the Jiashi STAR Biopharmaceutical ETF has achieved a one-year net value increase of 26.53%, with the highest monthly return since inception being 23.29% and the longest consecutive monthly gain lasting seven months [3]. - The average monthly return during the rising months of the Jiashi STAR Biopharmaceutical ETF is 7.85% [3]. Group 3: Industry Outlook - Recent adjustments in the pharmaceutical sector are attributed to a recovery in capital market financing and an increase in the scale of innovative drug exports, leading to a rebound in domestic innovative drug research and development [3]. - The outlook for the innovative drug sector remains focused on business development (BD) expectations, with BD activities typically accounting for about 40% of annual transactions in the fourth quarter [3]. - According to data, the top ten weighted stocks in the STAR Biopharmaceutical Index account for 49.74% of the index, indicating a concentration of investment in key players [4][6].

Core Viewpoint - Junshi Biosciences experienced a slight decline in stock price, with significant trading activity in both margin financing and securities lending, indicating high investor interest and potential volatility in the stock [1][2]. Financing Summary - On November 5, Junshi Biosciences had a financing buy-in amount of 39.95 million yuan, with a net buy of 572,900 yuan after repayments [1]. - The total margin financing and securities lending balance reached 1.404 billion yuan, with the financing balance accounting for 4.68% of the circulating market value, indicating a high level of leverage compared to the past year [1]. - The company’s financing balance of 1.391 billion yuan is above the 90th percentile of the past year, suggesting strong investor confidence [1]. Securities Lending Summary - On the same day, Junshi Biosciences repaid 4,500 shares in securities lending while selling 600 shares, with a total selling amount of 23,300 yuan based on the closing price [1]. - The remaining securities lending balance was 32,710 shares, with a total value of 12.697 million yuan, also exceeding the 90th percentile of the past year [1]. Company Overview - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase in losses [2]. - The number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2].

Macro Analysis - The report indicates that the current macro environment in Japan is conducive to moderate economic growth, with manageable debt sustainability, improving consumer sentiment, and favorable manufacturing investment trends [1] - The report anticipates an upward potential for the yen by 2026, while the Japanese stock market's previous gains have largely reflected policy expectations, suggesting that future market momentum will depend on the effectiveness of policy implementation [1] Financial Engineering - The report predicts a year-on-year decline in profit for the coal, steel, and cement industries, while float glass profitability is expected to show positive growth [2] - A slight decrease in the breeding sow inventory is noted, with stable recovery potential for pork prices expected until Q1 of next year [2] - Weak PMI data and housing sales indicate a need to monitor the potential resumption of infrastructure support expectations [2] Real Estate - In October, the sales of the top 10 and top 100 real estate companies increased by 6% and 4% month-on-month, respectively, but year-to-date sales show a decline of 16% and 17% year-on-year [3] - The report recommends focusing on structurally strong companies with high product reputation and strong sales rankings in core cities, such as China Merchants Shekou and China Jinmao [3] - Long-term growth potential in property services is highlighted, with recommendations for companies like China Merchants Jiyu and Greentown Service [3] Petrochemical - OPEC+ announced a production increase of 137,000 barrels per day in December and a pause in production plans from January to March 2026, which is expected to support oil prices in the short term [4] - The report maintains a positive outlook on the long-term investment value of major oil companies amid ongoing geopolitical uncertainties [4] Company Research - Sanyou Chemical's profitability has declined due to falling soda ash prices, leading to a downward revision of profit forecasts for 2025-2027 [7] - Aokai Co. has seen a continuous improvement in performance, although profit forecasts for 2025-2027 have been adjusted downward due to weaker-than-expected downstream demand [8] - Qiaoyuan Co. has optimized its product structure and expanded its market, resulting in an upward revision of profit forecasts for 2025-2026 [9] - Xiyes Co. reported a 17.81% year-on-year increase in revenue for the first three quarters of 2025, with a 35.99% increase in net profit [10] - China Metallurgical Group's revenue and net profit have declined significantly, but new contracts have shown positive growth [11] - Times Electric's revenue grew by 14.9% year-on-year, with a stable growth outlook for its rail transit equipment business [12] - Oulutong's revenue reached a record high in Q3, driven by strong demand for high-power server power supplies [13] - Junshi Biosciences has adjusted its profit forecasts downward due to ongoing R&D investments and the gradual ramp-up of product sales [14] - Jinjiang Hotels reported a decline in revenue but an increase in net profit margin, leading to a downward revision of profit forecasts for 2025-2027 [15]

2025 年 11 月 3 日 公司研究 特瑞普利单抗销售放量，研发持续推进 ——君实生物(688180.SH、1877.HK)2025 年三季报点评 要点 事件：公司发布 2025 年三季报，前三季度实现收入 18.06 亿元，同比增长 42.06%；归母净利润亏损 5.96 亿元，同比减亏 3.31 亿元；扣非归母净利润亏 损 6.70 亿元，同比减亏。其中 Q3 单季度收入 6.37 亿元，同比增长 31.40%； 归母净利润亏损 1.83 亿元；扣非归母净利润亏损 1.91 亿元。 点评： 特瑞普利单抗持续放量。公司核心产品特瑞普利单抗 25 年前三季度国内市场实 现销售收入约 14.95 亿元，同比增长约 40%。特瑞普利单抗的持续放量得益于 其不断扩大的适应症范围和全球商业化布局。2025 年三季度，特瑞普利单抗用 于一线治疗 HER2 表达尿路上皮癌的新适应症上市申请获得国家药监局受理。特 瑞普利单抗已在中国内地获批 12 项适应症，其中 10 项被纳入国家医保目录， 并在美国、欧盟等超过 40 个国家和地区获批上市。 研发投入持续强劲，管线推进有序。截至 2025 年三季度末，公司货币资金及交 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | | 1 RMB | | 260,295,700 | | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | | 1 RMB | | 260,295,700 | | ...

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, focusing on the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7] - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [7] - As of September 30, 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [8] Group 2: Product Development and Pipeline - The company has developed a robust product pipeline, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2] - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the EU, the UK, and Australia [2] - Junshi Biosciences is advancing its self-developed Tifcemalimab, the first anti-BTLA monoclonal antibody to enter clinical development, with two Phase III registration trials ongoing [2] Group 3: Collaborations and Future Prospects - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in preclinical development [3] - Junshi Biosciences aims to explore early-stage pipelines, with multiple products expected to initiate critical registration clinical trials by 2025 [2]